enGenes Biotech GmbH, Mooslackengasse 17, 1190 Vienna, Austria.
Department of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 11, 1190 Vienna, Austria.
Toxins (Basel). 2022 Jun 8;14(6):396. doi: 10.3390/toxins14060396.
Non-toxic derivatives of the cholera toxin are extensively used in neuroscience, as neuronal tracers to reveal the location of cells in the central nervous system. They are, also, being developed as vaccine components and drug-delivery vehicles. Production of cholera-toxin derivatives is often non-reproducible; the quality and quantity require extensive fine-tuning to produce them in lab-scale settings. In our studies, we seek a resolution to this problem, by expanding the molecular toolbox of the expression system with suitable production, purification, and offline analytics, to critically assess the quality of a probe or drug delivery, based on a non-toxic derivative of the cholera toxin. We present a re-engineered Cholera Toxin Complex (rCTC), wherein its toxic A1 domain was replaced with Maltose Binding Protein (MBP), as a model for an rCTC-based targeted-delivery vehicle. Here, we were able to improve the rCTC production by 11-fold (168 mg/L vs. 15 mg/L), in comparison to a host/vector combination that has been previously used (BL21(DE3) pTRBAB5-G1S). This 11-fold increase in the rCTC production capability was achieved by (1) substantial vector backbone modifications, (2) using strains capable of growth-decoupling (V strains), (3) implementing a well-tuned fed-batch production protocol at a 1 L scale, and (4) testing the stability of the purified product. By an in-depth characterization of the production process, we revealed that secretion of rCTC across the Outer Membrane (OM) is processed by the Type II secretion-system general secretory pathway (gsp-operon) and that cholera toxin B-pentamerization is, likely, the rate-limiting step in complex formation. Upon successful manufacturing, we have validated the biological activity of rCTC, by measuring its binding affinity to its carbohydrate receptor GM1 oligosaccharide (K = 40 nM), or binding to Jurkat cells (93 pM) and delivering the cargo (MBP) in a retrograde fashion to the cell.
无毒霍乱毒素衍生物在神经科学中被广泛用作神经元示踪剂,以揭示中枢神经系统中细胞的位置。它们也被开发为疫苗成分和药物递送载体。霍乱毒素衍生物的生产通常不可重复;为了在实验室规模下生产,需要进行广泛的微调以控制质量和数量。在我们的研究中,我们通过扩展表达系统的分子工具箱,包括合适的生产、纯化和离线分析,来解决这个问题,以便根据无毒霍乱毒素衍生物来批判性地评估探针或药物递送的质量。我们提出了一种经过重新设计的霍乱毒素复合物(rCTC),其中其毒性 A1 结构域被麦芽糖结合蛋白(MBP)取代,作为基于 rCTC 的靶向递送载体的模型。在这里,我们能够将 rCTC 的产量提高 11 倍(168mg/L 比之前使用的宿主/载体组合的 15mg/L)。与之前使用的宿主/载体组合(BL21(DE3) pTRBAB5-G1S)相比,rCTC 产量的 11 倍提高是通过以下方式实现的:(1)大量的载体骨架修饰;(2)使用能够解耦生长的菌株(V 菌株);(3)在 1L 规模下实施精心调整的分批生产方案;(4)测试纯化产物的稳定性。通过对生产过程的深入表征,我们揭示了 rCTC 通过 II 型分泌系统通用分泌途径(gsp 操纵子)穿过外膜(OM)进行分泌,并且霍乱毒素 B-五聚体化可能是复合物形成的限速步骤。在成功制造后,我们通过测量其与碳水化合物受体 GM1 寡糖的结合亲和力(K=40nM)或与 Jurkat 细胞的结合(93pM)以及以逆行方式向细胞递送货物(MBP),验证了 rCTC 的生物活性。